
    
      The phase II multicenter trial of vaccination study using peptides derived from URLC10,
      CDCA1, and KOC1 for locally advanced, recurrent or metastatic esophageal squamous cell
      carcinoma (ESCC) who had failed for the standard therapy are performed to evaluate the
      survival benefit of the cancer vaccination.
    
  